10 active not recruiting, 4 recruiting, 4 withdrawn, 3 suspended. 23 Phase 1, 9 Phase 2.
Follow X-Ray Imaging: new trials by email Literature Review of X-Ray Imaging trials Research Report on X-Ray Imaging
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 77 | 2027-04-09 | 2026-09-15 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2025-08-04 | 2025-07-03 | |
| Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer Bendamustine, Biopsy, Biospecimen Collection - Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-15 | 2025-04-01 | |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 1 | Active not recruiting | Mayo Clinic | 16 | 2024-04-11 | 2026-08-17 |
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Suspended | City of Hope Medical Center | 27 | 2024-02-19 | 2025-11-13 |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Abdullah Khan | 12 | 2023-12-21 | 2026-05-13 |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 65 | 2023-12-18 | 2026-10-27 |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Biopsy - High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2023-09-29 | 2026-03-05 |
| FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Balstilimab, Bevacizumab, Biospecimen Collection - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2023-05-03 | 2026-09-01 |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-07-14 |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography - Recurrent AL Amyloidosis, Refractory AL Amyloidosis | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-08-03 | 2026-07-31 |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Suspended | National Cancer Institute (NCI) | 66 | 2022-02-02 | 2026-08-17 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial Carfilzomib, Dexamethasone, Pomalidomide - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 39 | 2021-05-06 | 2026-02-25 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2020-07-17 | 2026-10-27 |
Showing 20 of 23. Sign in to see all of them.
Multiple Myeloma (4) · Neoplasm Metastasis (3) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Ovarian Neoplasms (2) · Bronchiolitis Obliterans Syndrome (1) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Chordoma (1) · Colonic Neoplasms (1) · Desmoid Tumors (1)
National Cancer Institute (NCI) (9) · Fred Hutchinson Cancer Center (6) · City of Hope Medical Center (3) · Children's Oncology Group (2) · Mayo Clinic (2) · Abdullah Khan (1)
United States (21) · Canada (3) · Australia (1)
Timothy A Yap (2) · Abdullah M Khan, MBBS, MSc (1) · Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1) · Amandeep Salhotra (1) · Amit J Sabnis (1) · Dwight H Owen (1) · Filippo Milano (1) · Fiona Simpkins (1) · Haider S Mahdi (1) · Jordan Gauthier (1) · Kristen Kelley (1) · Leslie L Popplewell (1) · Marwan G Fakih (1) · Mary F Wedekind Malone (1)
P30CA033572 (3), UM1CA228823 (3), UM1CA186688 (2), UM1CA186712 (2), P01CA078902 (1), P30CA015704 (1), U10CA180868 (1), UM1CA081457 (1), UM1CA186690 (1), UM1CA186717 (1)